Clinical trials: Rejection; Transplant, Liver
Liver Transplant Failure and Rejection, Children, Only
Histologic Evolution of Patients With Liver Transplantation
Certain pediatric liver transplant patients with immunosuppression levels in the therapeutic range and normal liver function tests present histological alterations (inflammation or fibrosis) in protocol biopsies.
- Trial name
- NCT06103097
- Testing
- No interventions done (obervational)
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Hospital Vall d'Hebron
Liver Transplant Rejection, Liver Transplant Failure and Rejection
Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients
Liver transplantation is a lifesaving procedure; however, there are chances that the body may reject the organ following liver transplantation, and this remains a significant concern.
- Trial name
- NCT06153641
- Testing
- N/A-Observational Study
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- St. Louis University
Evidence of Liver Transplantation, Rejection
Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation
This open-label clinical trial will evaluate the safety and efficacy of Alemtuzumab (Campath, Bayer Corp., Pittsburgh) in children (0-17) and adults (18-25) receiving intestinal transplant.
- Conditions
- Evidence of Liver Transplantation, Rejection, ALEMTUZUMAB
- Trial name
- NCT01208337
- Testing
- Alemtuzumab
- Volunteers
- 23 people
- Sponsor
- University of Pittsburgh
Immunosuppression, Kidney Transplant Rejection
The New LC-MS/MS Method for Determination of Unbound Tacrolimus in Plasma
Tacrolimus (TAC) is characterized by a narrow therapeutic window, as well as high inter- and intra-individual variability in pharmacokinetics. Both under- and overexposure may lead to severe adverse effects.
- Conditions
- Immunosuppression, Kidney Transplant Rejection, Kidney Transplant; Complications, Liver Transplant Rejection
- Trial name
- FreeTAC (NCT04657562)
- Testing
- Tacrolimus, Unbound tacrolimus measurement, CYP3A4 and CYP3A5 genotyping
- Where
- Poland
- Volunteers
- 380 people
- Sponsor
- National Science Centre, Poland
Liver Transplantation, Thymoglobulin
rATG Induction and Tacrolimus Monotherapy in Pediatric Liver Transplantation
This open-label clinical trial will evaluate the pharmacodynamics, pharmacogenomics and early efficacy and safety of steroid-free Tacrolimus (TAC) monotherapy and its minimization after induction with rabbit, anti-human thymocyte…
- Conditions
- Liver Transplantation, Thymoglobulin, Rejection
- Trial name
- NCT01207141
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Pittsburgh
Renal Insufficiency
Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction
Renal dysfunction in the context of liver transplantation is a major issue, with difficult patients' management and determining a worsened prognosis.
- Trial name
- ATG_HVH (NCT01453218)
- Testing
- ATeGe-Fresenius
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Hospital Vall d'Hebron
Intestinal Microbiota, Complication of Transplanted Liver
Human Microbiota and Liver Transplant
The microbiota represents the collections of microbial communities that colonize a host. In health, the microbiota protects against pathogens and maturation of the immune system.
- Conditions
- Intestinal Microbiota, Complication of Transplanted Liver, Acute Rejection of Liver Transplant, Infection
- Trial name
- NCT02223468
- Where
- Spain
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hospital Vall d'Hebron
Liver Transplant Rejection
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension
This was a multicenter, open-label, active-controlled study to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of two CFZ533 maintenance doses in de novo liver transplant recipients.
- Trial name
- CONTRAIL I (NCT03781414)
- Testing
- CFZ533, Tacrolimus - MMF - corticosteroids
- Where
- 29 sites in United States, Argentina and 8 more
- Volunteers
- 129 people
- Sponsor
- Novartis Pharmaceuticals
Liver Transplant Rejection, Immunosuppressant Adverse Reaction
Long-term Benefit of MPA in Liver Transplantation
MPA drugs are antiproliferative immunosuppressants and are widely used in solid organ transplantation. MPA drugs do not affect the recipient's kidney function and do not cause metabolic abnormalities and other problems.
- Trial name
- NCT05707520
- Testing
- enteric-coated mycophenolate (MPAs), None MPA
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Covid19, Kidney Transplant; Complications
Multicenter CTS Pre-and Post-Transplantation Covid-19 Serum Studies
The Covid-19 Serum Study is a prospective case-control study in 1. kidney or liver transplanted patients being hospitalized due to an infection with Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2) after…
- Conditions
- Covid19, Kidney Transplant; Complications, Kidney Transplant Failure and Rejection, Liver Transplant; Complications
- Trial name
- NCT04694573
- Where
- Germany
- Volunteers
- 600 people
- Sponsor
- Heidelberg University
Heart Failure, Respiratory Failure
Donor Simvastatin Treatment in Organ Transplantation
The aim of the study is to investigate the effects of donor simvastatin treatment on ischemia-reperfusion injury after heart transplantation.
- Conditions
- Heart Failure, Respiratory Failure, Liver Failure, Kidney Failure
- Trial name
- SIMVA (NCT01160978)
- Testing
- Simvastatin 80mg, Control Rx
- Where
- Finland
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Liver Transplantation
A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Liver Transplant Patients.
This 2 arm study will compare the efficacy and safety of two CellCept-containing treatment regimens in de novo liver transplant patients.
- Trial name
- NCT00545402
- Testing
- Mycophenolate mofetil, adjusted dose, Tacrolimus, Corticosteroids, IV
- Where
- 16 sites in France
- Volunteers
- 180 people
- Sponsor
- Hoffmann-La Roche
Liver Transplantation, Graft Versus Host Disease
The Effect of Human Leukocyte Antigen Macthing on Guiding Tacrolimus Regimen After Liver Transplantation
The aim of this research is to design a randomized controlled clinical study, which is based on HLA matching rate to guide tacrolimus regimen.
- Conditions
- Liver Transplantation, Graft Versus Host Disease, Graft Rejection, Drug-Related Side Effects and Adverse Reactions
- Trial name
- NCT03147157
- Testing
- tacrolimus regimen guided by HLA matching rate
- Volunteers
- 120 people
- Sponsor
- The First Hospital of Jilin University
Liver Transplant; Complications, Liver Transplant Rejection
Mortality, Morbidity and Risk Factors of Liver Retransplantation
This study aims to compare the short and long term outcomes of living donor and deceased donor liver retransplantation. Bearing that in mind, the investigators will retrospectively analyze the files of patients whom underwent a…
- Conditions
- Liver Transplant; Complications, Liver Transplant Rejection, Liver Transplant Failure, Liver Diseases
- Trial name
- NCT04789213
- Testing
- Liver Transplantation
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people
- Sponsor
- Memorial Bahçelievler Hospital
Liver Transplant Rejection
Graft Rejection or Tolerance Affected by Serial Change of Anti-donor Lymphocyte Antibody After Liver Transplantation
Liver is an organ that is well-known for its immune tolerant capacity. However, there were still controversial issues about the impact of immunologic challenge after liver transplantation on the graft function.
- Trial name
- NCT01444079
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Yonsei University
Liver Transplant Rejection
TRU-IMMUNO: Optimizing Liver Immunosuppression
This is a prospective, multi-center, randomized study. The primary objective is to evaluate the feasibility and utility of TruGraf/TRAC Liver testing used in addition to standard of care measures of liver dysfunction to guide…
- Trial name
- NCT05335551
- Testing
- Patients monitored with TruGraf and TRAC Liver testing
- Volunteers
- 130 people
- Sponsor
- Transplant Genomics, Inc.
Autoimmune Liver Disease, Autoimmune Hepatitis
TruGraf Liver Gene Expression Serial Test
This is an Investigator Initiated, single center, non-randomized, single arm study utilizing TruGraf liver gene expression serial testing in patients with autoimmune liver diseases (AIH, PSC, PBC) monthly for the first 6 months…
- Conditions
- Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis
- Trial name
- NCT06061341
- Testing
- TruGraf®
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Washington University School of Medicine
Liver Disease
Role of Tissue C4d in Differentiation Between Acut e Rejection and HCV Recurrence After Liver Transplantation
Assessment of the role of tissue C4d complement fragments in liver biopsy as a new marker for differentiating between acute rejection and Hepatitis C (HCV) recurrence in recipients post living donor liver transplantation (LDLT)…
- Trial name
- NCT02209675
- Testing
- liver biopsy
- Where
- Egypt
- Volunteers
- 25 people
- Sponsor
- Ain Shams University
Graft Rejection, Heart Transplantation
Diagnostic Validity of [18F]FSPG PET for the Assessment of Acute Rejection After Heart or Liver Transplantation
The a series of clinical studies of [18F]FSPG PET/CT showed that [18F]FSPG is safe and promising PET tracer for detecting inflammation with favorable biodistribution and pharmacokinetics in patients.
- Conditions
- Graft Rejection, Heart Transplantation, Liver Transplantation
- Trial name
- NCT04488094
- Testing
- [18F]FSPG
- Where
- South Korea
- Volunteers
- 7 people
- Sponsor
- Asan Medical Center
Side Effects of Calcineurin Inhibitors, Renal Toxicity
Switching From One Type of Anti-rejection Drug (Tacrolimus or Cyclosporine) to Another (Sirolimus) Approximately 90-180 Days After Liver Transplantation
Sirolimus can be safely switched as early as 90 days after liver transplantation with excellent tolerability and amelioration of the calcineurin inhibitor toxicity that initiated the switch.
- Conditions
- Side Effects of Calcineurin Inhibitors, Renal Toxicity, Hepatic Fibrosis on Biopsy, Neurotoxicity
- Trial name
- NCT00834496
- Testing
- Liver biopsy
- Where
- United States
- Sponsor
- Thomas Jefferson University